Post-Mensing Blues: Generic Mfrs. Still Face Product Liability Claims
Executive Summary
While the Supreme Court’s ruling last year found that failure-to-warn claims against generic manufacturers are preempted by federal law, some courts have refused to dismiss all claims.
You may also be interested in...
Generic Preemption Redux: Can Juries Deem A Drug Too Dangerous?
Supreme Court will decide in Mutual Pharmaceutical v. Bartlett whether generic drug manufacturers can be sued for alleged design defects; at issue is whether a jury can determine that a drug’s risks outweigh its benefits.
Supreme Court To Reconsider “Rules Of the Road” In Generic Preemption
Design defect claims made against generic companies are focus of a case involving Mutual Pharmaceutical’s generic sulindac; ruling may eliminate lower court carve-outs to its Mensing decision.
Will Withdrawal Of Generic Bupropion XL Resurrect Product Liability Litigation?
Personal injury firms began looking for clients after FDA announced that Impax/Teva’s generic product was not equivalent to GSK’s Wellbutrin XL, but Supreme Court’s Mensing decision may keep cases from getting off the ground.